{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:49:23Z","timestamp":1791474563386,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005676","name":"Jos\u00e9 Carreras Leukaemia Foundation","doi-asserted-by":"publisher","award":["R-09\/23"],"award-info":[{"award-number":["R-09\/23"]}],"id":[{"id":"10.13039\/501100005676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"Europ\u00e4ische Kommission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["EU-101055155"],"award-info":[{"award-number":["EU-101055155"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","award":["METH.14.08"],"award-info":[{"award-number":["METH.14.08"]}],"id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.exphem.2026.105918","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:48Z","timestamp":1791318948000},"page":"105918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prominin-1 (CD133) is essential for the determination of the phenotype of Philadelphia chromosome-positive leukemia"],"prefix":"10.1016","author":[{"given":"Anna","family":"Metodieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-0983","authenticated-orcid":false,"given":"Jana","family":"Karbanov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3758-1892","authenticated-orcid":false,"given":"Claudia","family":"Chiriches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsar Ali","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7961-1821","authenticated-orcid":false,"given":"Peter","family":"Carmeliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tjwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-3659","authenticated-orcid":false,"given":"Denis","family":"Corbeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-3811","authenticated-orcid":false,"given":"Martin","family":"Ruthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105918_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2026.105918_bib0002","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105918_bib0003","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/leu.2014.326","article-title":"PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation","volume":"29","author":"Mian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105918_bib0004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/71691","article-title":"Reversibility of acute B-cell leukaemia induced by BCR-ABL1","volume":"24","author":"Huettner","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2026.105918_bib0005","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2026.105918_bib0006","doi-asserted-by":"crossref","DOI":"10.1017\/pcm.2023.9","article-title":"Targeting BCR-ABL1-positive leukaemias: a review article","volume":"1","author":"Leak","year":"2023","journal-title":"Camb Prism Precis Med"},{"key":"10.1016\/j.exphem.2026.105918_bib0007","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105918_bib0008","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2026.105918_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105918_bib0010","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/sj.leu.2401516","article-title":"Philadelphia chromosome-positive cells are equally distributed in AC133+ and AC133- fractions of CD34+ peripheral blood progenitor cells from patients with CML","volume":"13","author":"Waller","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105918_bib0011","doi-asserted-by":"crossref","first-page":"8586","DOI":"10.1074\/jbc.M210640200","article-title":"Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins","volume":"278","author":"Fargeas","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2026.105918_bib0012","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1399-0039.2007.00825.x","article-title":"Nomenclature of prominin-1 (CD133) splice variants - an update","volume":"69","author":"Fargeas","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.exphem.2026.105918_bib0013","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1182\/blood.V90.12.5002","article-title":"AC133, a novel marker for human hematopoietic stem and progenitor cells","volume":"90","author":"Yin","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105918_bib0014","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1182\/blood.V90.12.5013","article-title":"A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning","volume":"90","author":"Miraglia","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.exphem.2026.105918_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s11658-024-00554-0","article-title":"Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease","volume":"29","author":"Pleska\u010d","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.exphem.2026.105918_bib0016","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood.V95.9.2813.009k20_2813_2820","article-title":"Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7","volume":"95","author":"Gallacher","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105918_bib0017","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2184.2006.00386.x","article-title":"Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor","volume":"39","author":"Freund","year":"2006","journal-title":"Cell Prolif"},{"key":"10.1016\/j.exphem.2026.105918_bib0018","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.stemcr.2014.09.016","article-title":"Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages","volume":"3","author":"G\u00f6rgens","year":"2015","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.exphem.2026.105918_bib0019","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1073\/pnas.1215438110","article-title":"CD133 is a modifier of hematopoietic progenitor frequencies but is dispensable for the maintenance of mouse hematopoietic stem cells","volume":"110","author":"Arndt","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105918_bib0020","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1074\/jbc.275.8.5512","article-title":"The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions","volume":"275","author":"Corbeil","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2026.105918_bib0021","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1523\/JNEUROSCI.2034-08.2009","article-title":"Loss of the cholesterol-binding protein prominin-1\/CD133 causes disk dysmorphogenesis and photoreceptor degeneration","volume":"29","author":"Zacchigna","year":"2009","journal-title":"J Neurosci"},{"issue":"23","key":"10.1016\/j.exphem.2026.105918_bib0022","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1073\/pnas.94.23.12425","article-title":"Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells","volume":"11","author":"Weigmann","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105918_bib0023","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/35023524","article-title":"Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane","volume":"2","author":"R\u00f6per","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2026.105918_bib0024","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/emmm.201100147","article-title":"Haematopoietic stem cell differentiation promotes the release of prominin-1\/CD133-containing membrane vesicles\u2013a role of the endocytic-exocytic pathway","volume":"3","author":"Bauer","year":"2011","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.exphem.2026.105918_bib0025","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899845","article-title":"Prominin-1 controls stem cell activation by orchestrating ciliary dynamics","volume":"15","author":"Singer","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2026.105918_bib0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/tra.12618","article-title":"Prominin-1 (CD133) modulates the architecture and dynamics of microvilli","volume":"20","author":"Thamm","year":"2019","journal-title":"Traffic"},{"key":"10.1016\/j.exphem.2026.105918_bib0027","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1242\/jcs.02439","article-title":"Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells","volume":"118","author":"Marzesco","year":"2005","journal-title":"J Cell Sci"},{"key":"10.1016\/j.exphem.2026.105918_bib0028","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1021\/bi900159d","article-title":"The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases","volume":"48","author":"Boivin","year":"2009","journal-title":"Biochemistry"},{"issue":"17","key":"10.1016\/j.exphem.2026.105918_bib0029","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1073\/pnas.1217002110","article-title":"Activation of PI3K\/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells","volume":"110","author":"Wei","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105918_bib0030","first-page":"378","article-title":"CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges","volume":"355","author":"Grosse-Gehling","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.exphem.2026.105918_bib0031","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1517\/14728220903005616","article-title":"Targeting CD133 antigen in cancer","volume":"13","author":"Ferrandina","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.exphem.2026.105918_bib0032","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V94.2.832","article-title":"AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors","volume":"94","author":"B\u00fchring","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105918_bib0033","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-2141.1999.01746.x","article-title":"Expression of AC133 and CD117 on candidate normal stem cell populations in childhood B-cell precursor acute lymphoblastic leukaemia","volume":"107","author":"Baersch","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2026.105918_bib0034","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3324\/haematol.2011.047191","article-title":"p185(BCR\/ABL) has a lower sensitivity than p210(BCR\/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia","volume":"97","author":"Mian","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105918_bib0035","first-page":"3409","article-title":"BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity","volume":"60","author":"Puccetti","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2026.105918_bib0036","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood-2003-03-0811","article-title":"Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571","volume":"102","author":"Beissert","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105918_bib0037","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"on behalf of the GMALL study group. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR\u2013ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105918_bib0038","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/ijc.23467","article-title":"Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR\/ABL","volume":"122","author":"Beissert","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2026.105918_bib0039","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1369\/jhc.2008.951897","article-title":"The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia","volume":"56","author":"Karbanov\u00e1","year":"2008","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.exphem.2026.105918_bib0040","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2010.180","article-title":"The t(6;9) associated DEK\/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation","volume":"24","author":"Oancea","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105918_bib0041","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105918_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080070","article-title":"Differential effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway in acute lymphoblastic leukemia","volume":"8","author":"Badura","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2026.105918_bib0043","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","article-title":"Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors","volume":"37","author":"Nijmeijer","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2026.105918_bib0044","doi-asserted-by":"crossref","first-page":"5244","DOI":"10.1158\/0008-5472.CAN-13-3012","article-title":"5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia","volume":"74","author":"Roos","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2026.105918_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7512632","article-title":"CD133 in Breast Cancer Cells: More than a Stem Cell Marker","volume":"2019","author":"Brugnoli","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.exphem.2026.105918_bib0046","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105918_bib0047","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105918_bib0048","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1634\/stemcells.2005-0290","article-title":"Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD\/SCIDbeta2mNull mice","volume":"24","author":"Pirson","year":"2006","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.exphem.2026.105918_bib0049","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2026.105918_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.118436","article-title":"Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites","volume":"254","author":"Marx","year":"2026","journal-title":"J. Biochem Pharmacol."},{"key":"10.1016\/j.exphem.2026.105918_bib0051","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.chembiol.2006.05.015","article-title":"A general strategy for creating \"inactive-conformation\" abl inhibitors","volume":"13","author":"Okram","year":"2006","journal-title":"Chem Biol"},{"key":"10.1016\/j.exphem.2026.105918_bib0052","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2026.105918_bib0053","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1021\/jm901808w","article-title":"A type-II kinase inhibitor capable of inhibiting the T315I \"gatekeeper\" mutant of Bcr-Abl","volume":"53","author":"Choi","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2026.105918_bib0054","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochimica et Biophysica Acta"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26005515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26005515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:50:21Z","timestamp":1791471021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26005515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"alternative-id":["S0301472X26005515"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105918","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prominin-1 (CD133) is essential for the determination of the phenotype of Philadelphia chromosome-positive leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}],"article-number":"105918"}}